Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-07-29

Last Posted Date: 2014-01-10

Lead Sponsor: St. Louis University

Target Recruit Count: 30

Registration Number: NCT00002627

Locations: 🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Biological: Filgrastim
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Decitabine (DAC)
Drug: Methotrexate
Drug: Methylprednisolone
Drug: Tacrolimus
Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation

First Posted Date: 2004-07-29

Last Posted Date: 2018-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT00002831

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-07-29

Last Posted Date: 2011-05-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT00002630

Locations: 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Tamoxifen in Treating Women With High-Risk Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-29

Last Posted Date: 2020-04-01

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 672

Registration Number: NCT00002542

Locations: 🇨🇦
Credit Valley Hospital, Mississauga, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Canada
🇨🇦
Stronach Regional Health Centre at Southlake, Newmarket, Canada

and more 45 locations

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2004-07-26

Last Posted Date: 2012-12-11

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT00005852

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-07-26

Last Posted Date: 2012-07-02

Lead Sponsor: Northwestern University

Registration Number: NCT00004169

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-22

Last Posted Date: 2012-02-22

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 61

Registration Number: NCT00003392

Locations: 🇺🇸
Bone Marrow Stem Cell Transplant Institute of Florida, Fort Lauderdale, Florida, United States
🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 11 locations

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Phase 3

Conditions: Leukemia

First Posted Date: 2004-07-19

Last Posted Date: 2009-12-23

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1520

Registration Number: NCT00002549

Locations: 🇵🇹
Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal
🇨🇿
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

and more 72 locations

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Lymphoma
Myelodysplastic Syndromes
Multiple Myeloma and Plasma Cell Neoplasm
Leukemia

First Posted Date: 2004-07-19

Last Posted Date: 2013-06-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002502

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-07-16

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00003877

Locations: 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy